Related Experiment Video
Updated: Jul 8, 2026
07:29
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Diabetes and Lipids: A Review and Update on Lipid Biomarkers and Cardiovascular Risk
Yumiko Tsushima1, Betul Hatipoglu2
1University Hospitals Cleveland Medical Center, Department of Medicine, Diabetes & Obesity Center, Mayfield Heights, Ohio; Case Western Reserve University School of Medicine, Mayfield Heights, Ohio.
Summary
New lipid biomarkers like non-high-density lipoprotein cholesterol help identify cardiovascular risk in diabetes patients. Treatment targets and therapies are continuously updated for better patient outcomes.
Area of Science:
- Endocrinology and Metabolism
- Cardiovascular Disease Research
- Lipidology
Background:
- Diabetes mellitus is strongly associated with dyslipidemia, a major risk factor for cardiovascular disease.
- Traditional lipid markers may not fully capture the complex cardiovascular risk in individuals with diabetes.
- Evolving evidence highlights the need for updated risk assessment and management strategies.
Purpose of the Study:
- To synthesize current and emerging evidence on the relationship between diabetes and dyslipidemia.
- To update knowledge on lipid biomarkers for cardiovascular risk assessment in diabetic patients.
- To reflect changes in clinical guidelines for managing dyslipidemia in diabetes.
Main Methods:
- Comprehensive literature review of MEDLINE/PubMed database.
- Inclusion of English articles primarily published between 1994 and early 2025.
- Incorporation of guidelines from national and international professional organizations in diabetes, lipids, and cardiovascular disease.
Main Results:
- Studies confirm a significant link between diabetes and hypertriglyceridemia.
- Emerging lipid biomarkers include apolipoprotein B, non-high-density lipoprotein cholesterol, and lipoprotein (a).
- Lipid variability is recognized as a crucial factor in cardiovascular risk stratification.
Conclusions:
- Non-low-density lipoprotein cholesterol and other advanced lipid markers improve cardiovascular risk stratification in diabetes.
- Treatment targets and pharmacological interventions for dyslipidemia in diabetes are continually evolving.
- Ongoing research refines the management of lipid abnormalities to prevent cardiovascular events in diabetic populations.
Related Concept Videos
01:24Overview of Lipid Metabolism
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...